Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis

J Control Release. 2019 Nov 28:314:62-71. doi: 10.1016/j.jconrel.2019.10.038. Epub 2019 Oct 22.

Abstract

Cystic fibrosis (CF) is a serious lung disease, commonly susceptible to Pseudomonas aeruginosa colonization. The dense mucus together with biofilm formation limit drug permeability and prevent the drug from reaching the site of action, causing treatment failure of the bacterial infection. Besides the use of antibiotics, the mucolytic agent N-acetylcysteine (NAC) is recommended to be co-administered in the treatment of CF. Although several formulations have been developed for inhalation therapy to improve the pulmonary condition in CF patients, there is still no comprehensive study on a combined multifunctional dry powder formulation of antibiotics with NAC. In this work, we developed an innovative multifunctional dry powder inhaler (DPI) formulation based on salt formation between NAC and antibiotics and characterized their solid state properties and physical stability. NAC could be spray dried together with three different antibiotics, azithromycin (Azi), tobramycin (Tobra) and ciprofloxacin (Cipro), without the use of organic solvents to form Azi/NAC, Tobra/NAC and Cipro/NAC DPI formulations. Solid-state characterization of these DPI formulations showed that they were amorphous after spray drying. Azi/NAC and Tobra/NAC form co-amorphous salt systems that were physically stable under storage at stress conditions. For particle characterization, the obtained mass median aerodynamic diameters were in a suitable range for inhalation (< 5.0μm). The multifunctional antibiotic/NAC formulations conserved or improved the antibiotic susceptibility and showed promising results regarding the inhibition of P. aeruginosa PA14 biofilm formation.

Keywords: Antibiotics; Bacterial infection; Co-amorphous drug delivery; Dry-powder formulation; Inhalation; Salt formation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / administration & dosage*
  • Acetylcysteine / pharmacology
  • Administration, Inhalation
  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacology
  • Azithromycin / administration & dosage
  • Azithromycin / pharmacology
  • Biofilms / drug effects*
  • Ciprofloxacin / administration & dosage
  • Ciprofloxacin / pharmacology
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / drug therapy*
  • Drug Stability
  • Drug Storage
  • Expectorants / administration & dosage
  • Expectorants / pharmacology
  • Horses
  • Mucus / microbiology
  • Particle Size
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / physiology
  • Tobramycin / administration & dosage
  • Tobramycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Expectorants
  • Ciprofloxacin
  • Azithromycin
  • Tobramycin
  • Acetylcysteine